Dynasty Wealth Management LLC Buys New Stake in BioNTech SE (NASDAQ:BNTX)

Dynasty Wealth Management LLC acquired a new stake in BioNTech SE (NASDAQ:BNTX) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 4,242 shares of the company’s stock, valued at approximately $391,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Dynamic Technology Lab Private Ltd boosted its holdings in BioNTech by 2.5% in the 4th quarter. Dynamic Technology Lab Private Ltd now owns 4,666 shares of the company’s stock valued at $492,000 after purchasing an additional 116 shares during the last quarter. Covestor Ltd increased its position in shares of BioNTech by 47.2% in the 1st quarter. Covestor Ltd now owns 415 shares of the company’s stock valued at $38,000 after purchasing an additional 133 shares during the last quarter. GAMMA Investing LLC increased its position in shares of BioNTech by 121.0% in the 1st quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock valued at $25,000 after purchasing an additional 150 shares during the last quarter. Arlington Capital Management Inc. increased its position in shares of BioNTech by 10.0% in the 1st quarter. Arlington Capital Management Inc. now owns 2,200 shares of the company’s stock valued at $203,000 after purchasing an additional 200 shares during the last quarter. Finally, Midwest Professional Planners LTD. grew its position in shares of BioNTech by 7.2% in the 1st quarter. Midwest Professional Planners LTD. now owns 3,177 shares of the company’s stock valued at $293,000 after buying an additional 212 shares during the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Stock Performance

Shares of BNTX traded down $0.14 during mid-day trading on Wednesday, hitting $86.60. The company’s stock had a trading volume of 223,567 shares, compared to its average volume of 686,319. The stock’s 50-day moving average is $89.10 and its two-hundred day moving average is $91.13. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.16 and a current ratio of 11.38. The firm has a market capitalization of $20.59 billion, a PE ratio of 172.72 and a beta of 0.23. BioNTech SE has a one year low of $78.02 and a one year high of $125.83.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Monday, May 6th. The company reported ($1.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.60). The company had revenue of $203.69 million for the quarter, compared to analyst estimates of $589.96 million. BioNTech had a return on equity of 0.55% and a net margin of 4.01%. As a group, sell-side analysts anticipate that BioNTech SE will post -2 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently commented on BNTX shares. Evercore ISI initiated coverage on shares of BioNTech in a research report on Tuesday, May 14th. They issued an “inline” rating and a $100.00 target price on the stock. TD Cowen raised their target price on shares of BioNTech from $95.00 to $98.00 and gave the company a “hold” rating in a report on Tuesday, May 7th. HC Wainwright reissued a “buy” rating and issued a $113.00 target price on shares of BioNTech in a research report on Wednesday, June 26th. Finally, BMO Capital Markets reduced their price target on shares of BioNTech from $123.00 to $122.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 7th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $111.70.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.